Anti-Human PD-L1 (Atezolizumab) [RG7446] — APC
Anti-Human PD-L1 (Atezolizumab) [RG7446] — APC
Product No.: LT1751
Product No.LT1751 Clone RG7446 Target PD-L1 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Programmed Death Ligand 1, B7-H1, PD-L1, CD274 Isotype Human IgG Applications FC , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Unknown Product Concentration 0.2 mg/ml Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (650 nm) Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Atezolizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Atezolizumab. Atezolizumab recognizes an epitope on mouse PD-L1. This product is for research use only. Background PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction. Antigen Distribution PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. Ligand/Receptor PD-1 (PDCD1) Research Area Biosimilars . Cancer . Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Atezolizumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA to enable accurate and consistent quantification of drug concentration in serum samples. In a PK bridging ELISA:
Validation and quality control:
Summary Table: Atezolizumab Biosimilar Use in PK Bridging ELISA
Using research-grade biosimilars as standards enables consistent, robust, and comparable PK quantification, facilitating biosimilar approval and monitoring. Standard flow cytometry protocols using a conjugated Atezolizumab biosimilar (such as PE or APC-labeled) to validate PD-L1 expression or binding capacity typically involve direct or indirect staining methods, including proper controls and quantification strategies. Protocol Overview:
Binding Validation and Specificity Controls:
Representative Reference Details:
Experimental Notes:
Limitations:
To summarize, conjugated Atezolizumab biosimilars are applied in standard direct staining protocols, with robust control strategies to quantitatively and specifically measure PD-L1 on diverse cell types by flow cytometry. Biopharma companies confirm the structural and functional similarity of a proposed biosimilar to the originator drug using a comprehensive suite of analytical assays that rigorously compare critical quality attributes (CQAs) at every molecular level. Essential analytical assays typically performed include:
Role of Leinco biosimilars in these studies:Leinco Technologies provides high-quality biosimilar reference standards, critical for:
In summary, the demonstration of biosimilar comparability is anchored in detailed, multi-level analytical characterization using orthogonal methods, with biosimilar standards like those from Leinco supporting assay robustness and comparability throughout the workflow. References & Citations1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed 2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. 3. Freeman, G. et al. (2000) J. Exp. Med. 192:1027. Technical ProtocolsCertificate of Analysis |
Formats Available
